grant
microRNA-controlled mRNA therapeutics
Organization ICAHN SCHOOL OF MEDICINE AT MOUNT SINAILocation NEW YORK, UNITED STATESPosted 1 Apr 2024Deadline 31 Jan 2028
NIHUS FederalResearch GrantFY20262019 novel corona virus2019 novel coronavirus2019-nCoV3' Untranslated Regions3'UTRAffectAnimalsAntibodiesAntibody ResponseAntigen PresentationAntigen-Presenting CellsAntigensB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellBiodistributionCOVID-19 virusCOVID19 virusCell BodyCellsCoV-2CoV2DataDrug DeliveryDrug Delivery SystemsDrug FormulationsDrug usageDrugsEndotheliumFDA approvedGene TranscriptionGenetic TranscriptionGoalsHematopoieticHepatic CellsHepatic Parenchymal CellHepatocyteHumanImmune Cell ActivationImmune responseImmunityImmunizationImmunologic SubtypingImmunophenotypingIn VitroInjectionsLiver CellsMedicationMedicineMessenger RNAMicroRNAsModelingModern ManMuscle CellsMyocytesNerve CellsNerve UnitNeural CellNeurocyteNeuronsNon-Polyadenylated RNANucleosidesOrganOutcomePatternPharmaceutical PreparationsPhenotypePopulationProgenitor CellsProtein Replacement TherapyProteinsPublishingRNARNA ExpressionRNA Gene ProductsRNA vaccineRNA-based vaccineReporterReportingRibonucleic AcidSARS corona virus 2SARS-CO-V2SARS-COVID-2SARS-CoV-2SARS-CoV2SARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-related corona virus 2SARS-related coronavirus 2SARSCoV2Severe Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome related corona virus 2SiteSpecificityT-CellsT-LymphocyteTechnologyTestingTherapeuticTranscriptionTransfectionTransgenesWorkWuhan coronavirusaccessory celladaptive immunityantigen-specific T cellscell typecoronavirus disease 2019 viruscoronavirus disease-19 virusdrug usedrug/agentenzyme replacement therapyenzyme replacement treatmentexpression vectorhCoV19hemopoietichost responseimmune activationimmune system responseimmunogenimmunoresponsein vivo Modellipid based nanoparticlelipid nanoparticlemRNAmRNA vaccinemRNA-based vaccinemiRNAnCoV2native protein drugneuronalnovelpharmaceutical proteinpreventpreventingprotein drug agentprotein expressionprotein-based drugspatial RNA sequencingspatial gene expression analysisspatial gene expression profilingspatial resolved transcriptome sequencingspatial transcriptome analysisspatial transcriptome profilingspatial transcriptome sequencingspatial transcriptomicsspatially resolved transcriptomicsspatio transcriptomicsstem cellstherapeutic proteinthymus derived lymphocytetransgenetransgene expressionvaccine efficacyvector
Description preview
Nucleoside modified RNA-based drugs (modRNA) are a powerful new class of medicine. One type of modRNA, RNA vaccines, has been pivotal in immunization to SARS-CoV-2. modRNA is delivered via lipid nanoparticles (LNP), and antigen presented by whichever cells take up and expresses the modRNA. The identity and phenotypic state of cells presenting…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click